Market capitalization | $114.66m |
Enterprise Value | $92.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.77 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-43.82m |
Free Cash Flow (TTM) Free Cash Flow | $-31.18m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:
5 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.61 -0.61 |
115%
115%
|
|
EBITDA | -43 -43 |
29%
29%
|
EBIT (Operating Income) EBIT | -44 -44 |
29%
29%
|
Net Profit | -43 -43 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
Head office | Canada |
CEO | Joseph Oliveto |
Employees | 47 |
Founded | 2003 |
Website | www.milestonepharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.